China has put Illumina on its ‘unreliable entity list’ after the US imposed sanctions on Beijing Genomics Institute, also a ...

Illumina's leading sequencing technology, as well as its menu of DRAGEN-powered multiomics offerings, genomics AI tools and Illumina Connected Analytics platform, has streamlined genomic data ...

Analysts said the move comes amid rising trade tensions with the U.S. and as Illumina faces stiff competition in China’s ...

Illumina, Inc. (NASDAQ: ILMN), a global leader in genomic sequencing and analysis, today announced it is collaborating with NVIDIA to advance technology platforms for the analysis and ...

Illumina's (ILMN) stock slid 5% post-market after it released its Q4 earnings report and reiterated its 2025 guidance, ...

The general mood among these heavyweight investors is divided, with 37% leaning bullish and 37% bearish. Among these notable options, 4 are puts, totaling $366,099, and 4 are calls, amounting to ...

Illumina shares tumbled 8% Friday on investor concerns about the future of the gene-sequencing equipment maker’s business in China, growing competitive threats, and the potential for Trump ...

After China placed Illumina on a government watchlist this week, in response to new tariffs imposed by the Trump ...

TD Cowen downgraded Illumina (ILMN) to Hold from Buy with a price target of $140, down from $177. Accelerating high throughput next-generation ...

Illumina (ILMN-1.73%) is the industry leader in using short-read sequencing technology, which breaks DNA into short segments to aid in analysis for genetic research, testing, and medical treatment.